Eli Lilly & Co. has its eyes on expanding in the technology that has helped turn the tide in the coronavirus pandemic, with a new finance chief who has deep roots in the company building on a strategy years in the making.
Like many other companies that watched as a new breed of vaccines helped provide millions of people around the world with strong protection against the ravages of severe Covid-19, Lilly is interested in RNA technology. But it is also wary of overpaying for assets in a market where other investors have been pouring in cash in hopes of latching on to the next big thing.
"crowded" - Google News
January 12, 2022 at 01:30AM
https://ift.tt/3FhdPBF
Eli Lilly Is Among the Crowded Field Pursuing RNA Therapies - Bloomberg
"crowded" - Google News
https://ift.tt/39CzplD
https://ift.tt/3c6iubT
Bagikan Berita Ini
0 Response to "Eli Lilly Is Among the Crowded Field Pursuing RNA Therapies - Bloomberg"
Post a Comment